29mon MSN
Halozyme outlines $1.71B–$1.81B 2026 revenue target as new subcutaneous technologies expand pipeline
Q4 2025 Management View Helen Torley, President and CEO, highlighted that "2025 was one of the most significant and value-creating years in Halozyme's history," citing the expansion of the portfolio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results